Pheon Therapeutics
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Lawes Open Innovation Hub Rothamsted Res...Website
www.pheontx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Pheon Therapeutics
Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. Pheon is backed by expert, specialist healthcare investorExplore more
Pheon Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pheon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Pheon Therapeutics recently announced quarterly report
Product Launch: Get notified when Pheon Therapeutics launches new products
Pheon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Pheon Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Pheon Therapeutics
Website visits: Recent activity has been detected on your website
Click to see if Pheon Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Pheon Therapeutics has new funding data
Check if Pheon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Pheon Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Pheon Therapeutics
Compare insights from companies similar to Pheon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pheon Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pheon Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pheon Therapeutics.
Pheon Therapeutics financials insights
Gather financial insights about Pheon Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$68M
2024
Series B
$120M
Pheon Therapeutics Tech Stack
A closer look at the technologies used by Pheon Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Funding
Funding
New Hire
Executive Move
Left Company
Executive Move
Pheon Therapeutics News & Media
Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
Dr. Kariuki brings a wealth of experience in ADCs, across corporate strategy, finance and operations Advancement of Pheon's differentiated ADC pipeline, accelerating first program, PHN-010, into clinical development this year LONDON, Sept. 10, 2024 /PRNewswire/ -- Pheon Therapeutics...Pheon Raises $120M in Series B to Advance ADCs for Hard-to-Treat Cancers - BioSpace
London-based Pheon Therapeutics will use the funds to push its three lead antibody-drug conjugate candidates through clinical proof-of-target studies.Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
Financing led by TCGX, including new investment from BVF Partners, Lightspeed Venture Partners (Lightspeed) and Perceptive Advisors Three first-in-class ADC assets funded through clinical proof of concept LONDON, May 21, 2024 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading...Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer
Dr. Yang brings extensive experience in leading early-stage clinical trials and late stage global registrational trials LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pheon Therapeutics
Sign Up For FreeTo access detailed company insights
Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a first-in-class ADC against a novel target that is highly expre... Read More
